Entries |
Document | Title | Date |
20080206340 | Galactomannans and/or Glucomannans For Increasing the Bioavailability of Active Substances - The invention relates to a method for increasing the bioavailability of nutrients by using polysaccharides such as galactomannans and similar for introducing active substances, e.g. the human growth hormone HGH and others, into the human or animal metabolism. The aim of the invention is to further develop the production of polysaccharides such as galactomannans and glucomannans in such a way that the same are also suitable for introducing active substances such as the human growth hormone into the human or animal metabolism. | 08-28-2008 |
20080220068 | TREATMENT AND PREVENTION OF EXCESSIVE SCARRING - A pharmaceutical composition comprised of a hydration agent and an anesthetic can be used to treat excessive scarring conditions, such as keloid and hypertrophic scars. | 09-11-2008 |
20080226726 | 3D-Cardiac Tissue Engineering For the Cell Therapy of Heart Failure - A pharmaceutical composition comprising biodegradable gel-based matrix, at least one active agent and stem cells able to differentiate into cardiac tissue under the form of a patch, for the treatment of heart failure due to myocardial infarction is disclosed. | 09-18-2008 |
20080241250 | IN VIVO BIOREACTORS AND METHODS OF MAKING AND USING SAME - The present invention relates to an in vivo method of promoting the growth of autologous cartilage and bone tissue, including tissue that can be explanted to other locations in the subject. | 10-02-2008 |
20080254125 | Processing of Chitosan and Chitosan Derivatives - An article containing N-acylchitosan is manufactured by a process comprising the steps of providing a mixture containing chitosan and/or N-acylchitosan, and extruding the mixture to form an N-acylchitosan hydrogel. Alternatively, the process comprising the steps of providing a chitosan and/or N-acylchitosan hydrogel, and extruding the hydrogel. An article with a memorized shape is formed by fixing the N-acylchitosan hydrogel in a desired shape, and at least partially drying the fixed hydrogel. A patient is treated by injecting the N-acylchitosan hydrogel. | 10-16-2008 |
20080260836 | Films Comprising a Plurality of Polymers - Films are disclosed that comprise a first polymer and a second polymer having a solubility temperature lower than that of the first polymer; wherein the breaking strength of the film is greater than about 750 psi (5,171 kPa). Also disclosed are compositions comprising such films that are useful as oral care, personal care or home care compositions. Methods of using such compositions are also disclosed. | 10-23-2008 |
20080260837 | Physically stable aqueous suspensions of active pharmaceuticals - The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water; a water soluble, low viscosity grade cellulose polymer with a viscosity range of 3 mPa·s to 50 mPa·s as a surfactant; a suspending agent; and water. | 10-23-2008 |
20080274191 | Bioadhesive Composition With Programmed Release - The invention relates to novel viscous liquid compositions for producing pasty forms having a prolonged action and/or release for local applications. These compositions are characterized in that the long-lasting action and/or the prolonged release of the active substance is obtained by the in-situ formation of a matrix film having an increased bioadhesive power and being more or less viscous and biodegradable. The invention also relates to a viscous liquid composition with an increased bioadhesive power for a local application in pasty form with a prolonged release of an active substance, whereby being characterized in that it contains at least one matrix agent, a medium for hydrating the matrix agent, and at least one active substance. | 11-06-2008 |
20080274192 | Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor - A pharmaceutical composition comprising the compound 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, or a pharmaceutically acceptable salt or solvate thereof, in an amorphous form. | 11-06-2008 |
20080279945 | GEL-BASED DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS - Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of mammalian, and in particular, human diseases, including for example, cardiac disease or dysfunction, and musculoskeletal disorders and congenital myopathies, including, for example, muscular dystrophy, acid maltase deficiency (Pompe's disease), and the like. In illustrative embodiments, the invention provides rAAV vectors comprised within a biocompatible gel composition for enhanced viral delivery/transfection to mammalian tissues, and in particular to vertebrate muscle tissues such as a human heart or diaphragm tissue. | 11-13-2008 |
20080317861 | Polymeric Materials and Methods - Chimeric polymer compositions and methods are provided in which a plurality of carbohydrate moieties and amino acids form the backbone of a polymer. Most preferably, the polymer includes alternating saccharide and peptide portions to form the chimeric polymer. | 12-25-2008 |
20090004275 | Composition for Delivery of an Active Agent - A composition for oromucosal delivery of a biologically active agent, which composition releases the active agent within 5 minutes when applied to an oramucosal surface in use, comprises a biologically active agent and a matrix-former. The biologically active agent may be present as an ion pair complex. | 01-01-2009 |
20090004276 | Novel injectable chitosan mixtures forming hydrogels - A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions. | 01-01-2009 |
20090041846 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 02-12-2009 |
20090061000 | PHARMACEUTICAL FORMULATION USE 030 - An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF | 03-05-2009 |
20090081296 | Extracorporeal cell-based therapeutic device and delivery system - Extracorporeal cell-based therapeutic devices and delivery systems are disclosed which provide a method for therapeutic delivery of biologically active molecules produced by living cells in response to a dynamic physiologic environment. One embodiment includes long hollow fibers in which a layer of cells are grown within the intraluminal volume or within a double hollow-filled chamber. Another embodiment includes a wafer or a series of wafers providing a substrate onto which cells are grown. The wafer(s) are inserted into a device. A device may deliver a pre-selected molecule, for example, a hormone, into a mammal's systemic circulation and/or may deliver a member of different cell products. The device is adapted to secure viable cells which produce and secrete the pre-selected molecule into blood or fluid. The invention also provides a minimally invasive method for percutaneously introducing into a preselected blood vessel or body cavity the device of the invention. | 03-26-2009 |
20090087490 | EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION - A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α | 04-02-2009 |
20090104266 | 3-(2-DIMETHYLAMINOMETHYLCY CLOHEXYL)PHENOL RETARD FORMULATION - The invention relates to a dosage form for controlled release of the active ingredient 3-(2-dimethylaminomethylcyclohexyl)phenol, preferably (1R,2R)-3-(2-dimethylamino-methylcyclohexyl)phenol, or one of the pharmaceutically acceptable salts thereof, which
| 04-23-2009 |
20090104267 | SOFT TABLET CONTAINING HIGH MOLECULAR WEIGHT CELLULOSICS - The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses exceptionally good mouthfeel and stability. | 04-23-2009 |
20090110735 | CONTROLLED RELEASE FORMULATIONS - The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body. | 04-30-2009 |
20090123547 | Methods and Compositions for Regenerating Connective Tissue - Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament. | 05-14-2009 |
20090136576 | Biocompatible composition for replacing/regenerating tissues - A biocompatible composition for replacing/regenerating articular tissues, in particular tissues of the nucleus pulposus but also not articular tissues such as bony tissues, providing a hydrogel matrix comprising a first and a second natural polymer, cells adapted to regenerate the tissue of the disc core, a cross linking agent suitable to cross-link at least one of said natural polymers in situ, thus giving to the biocompatible composition an appropriate resistance, and molecules adapted to stimulate the growth and/or the differentiation of cells, wherein one of the two natural polymers is sodium alginate. In a particular exemple, the above described composition before the cross-linking step has a starting density such that it is injectable. In particular, the cross linking action on sodium alginate is caused by a cross linking agent contained in biodegradable polymeric particles, released in a controlled way from natural polymers, for example gelatin, or starting from synthetic polymers, for example polylactic acid or copolymers of acid lactic-glycolic acid. | 05-28-2009 |
20090202639 | Biomaterials Consisting of Sulphated Hyaluronic Acid and Gellan to be Used in the Prevention of Spinal Adhesions - New biomaterials consisting of a combination of sulphated hyaluronic acid and gellan (as well as gellan that has not been associated with other polymers), to be used as a highly effective barrier to prevent post-surgical adhesions in abdominal, pelvic and, above all, spine surgery. | 08-13-2009 |
20090202640 | HYDROGELS OF POLYSACCHARIDE MIXTURES FOR TISSUE ENGINEERING AND AS CARRIERS OF ACTIVE COMPOUNDS - The present invention describes the preparation of hydrogels (or 3D matrices) obtainable from aqueous solutions of mixtures of acid polysaccharides and derivatives of basic polysaccharides, such as oligosaccharide derivatives of chitosan. Said solutions are suitably gelled with either chemical or physical gelling agents with the aim of encapsulating either cells, isolated or in multicellular associations, or pharmacologically active molecules, in solution or suspension, for use in the biomedical and pharmaceutical field. | 08-13-2009 |
20090202641 | HOLLOW FIBROUS ORGANIC NANOTUBE AND PRODUCTION METHOD THEREOF - Disclosed is a method of synthesizing a water-free nanotube capable of efficiently encapsulating a functional substance therein, in large quantities. The method comprises: dissolving, in an organic solvent heated up to a temperature equal to or less than a boiling point thereof, an N-glycoside type glycolipid represented by the following general formula (1): G-NHCO—R | 08-13-2009 |
20090202642 | Drug Delivery System Comprising Microparticles and Gelation System - Disclosed are drug delivery compositions comprising a continuous aqueous phase comprising a reverse thermal gelation system comprising a blend of a cellulose derivative and polyethylene glycol; a discontinuous particulate phase comprising microparticles; and an agent to be delivered contained in at least said discontinuous particulate phase. Also disclosed are sustained release compositions formed using the drug delivery compositions and methods of using those compositions. | 08-13-2009 |
20090214653 | Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 4 (BMP-4) and nucleotide molecules encoding the proteins and host cells expressing the proteins. The present invention relates also to the use of the BMP-4 for treating disorders related to bone and cartilage formation. Osteogenic devices and pharmaceutical compositions containing the proteins are also disclosed. | 08-27-2009 |
20090214654 | TREATMENT OF ANEURYSM WITH APPLICATION OF CONNECTIVE TISSUE STABILIZATION AGENT IN COMBINATION WITH A DELIVERY VEHICLE - Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles. | 08-27-2009 |
20090220608 | PHARMACEUTICAL COMPOSITION OF MICROSPHERES FOR PREVENTING DIABETIC FOOT AMPUTATION - The present invention relates to a pharmaceutical composition that comprises polymeric microspheres containing epidermal growth factor (EGF) for the application, by the parenteral route, into the lower limbs of diabetic patients with cutaneous chronic ischemic ulcerative wounds. The pharmaceutical composition described herein, in contrast with the state of the art, is useful because reduce the administration frequency during the treatment and allows for the healing of the ulcerative wounds in a shorter time interval with respect to the injection of equivalent quantities of non-encapsulated EGF. | 09-03-2009 |
20090252800 | Anisotropic nanocomposite hydrogel - Anisotropic nanocomposite hydrogel materials are created using a process in which a hydrogel-forming material is crosslinked in the presence of nanoscale cellulose and subsequently thermally cycled under an applied tensile strain. Such materials are capable of exhibiting high mechanical and viscoelastic anisotropy, increased stiffness when subjected to large strain, and are suitable for a broad range of soft tissue replacement applications. In addition controlled release of bioactive agents properties can be designed into medical devices fabricated from such nanocomposite materials. | 10-08-2009 |
20090269407 | Poly-alpha(1-4)glucopyranose-based matrices with hydrazide crosslinking - The present invention provides biocompatible, biodegradable matrices formed from poly-α(1→4)glucopyranose and reactive hydrazide groups. The matrices can be used for various applications in the body, including drug delivery and cell therapy. | 10-29-2009 |
20090285897 | REHYDRATABLE THIOLATED POLYSACCHARIDE PARTICLES AND SPONGE - Tissue and other body structures may be protected using a hydrated composition made from free-flowing rehydratable particles or a rehydratable sponge comprising substantially collagen-free dehydrothermally crosslinked thiolated polysaccharide. Rehydration of crosslinked or uncrosslinked polysaccharide particles may be carried out without clumping by dispersing the particles in a biocompatible water-miscible polar dispersant such as ethanol and combining the dispersion with sufficient aqueous solvent for the particles to convert them to a cohesive hydrogel. The hydrated particles or sponge may assist in returning an injured, inflamed or surgically repaired surface to a normal state, e.g., through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function. | 11-19-2009 |
20100008992 | TREATMENT OF DISC DEGENERATIVE DISEASE AND COMPOSITIONS FOR SAME - Methods and compositions for treating or ameliorating lower back pain by administering an effective amount of one or more cell types, alone, and/or in combination with a matrix, and/or in combination with growth factors, in order to stimulate lumbar angiogenesis, decrease inflammation, and stimulating regeneration. | 01-14-2010 |
20100015231 | LOW SWELL, LONG-LIVED HYDROGEL SEALANT - A low swell, long-lived hydrogel sealant formed by reacting a highly oxidized polysaccharide containing aldehyde groups with a multi-arm amine is described. The hydrogel sealant may be particularly suitable for applications requiring low swell and slow degradation, for example, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants; neurosurgery applications, such as sealing the dura; and as a plug to seal a fistula or the punctum. The low swell, long-lived hydrogel sealant may also be useful as a tissue sealant and adhesive, and as an anti-adhesion barrier. | 01-21-2010 |
20100021545 | INJECTABLE IN SITU SELF-FORMING MINERAL-POLYMER HYBRID COMPOSITION AND USES THEREOF - Self-forming hybrid compositions consisting in admixed liquid and solid components enable the formation of bio-materials. The present invention proposes a) a thermo-sensitive self-forming liquid component, being water-based and containing at least a polycationic polymer such as chitosan, and an organic mono-phosphate source, which is a solution at a pH ranging from 6.5 to 7.4; b) a solid component being mineral and composed of at least one of calcium, fluoride, strontium, carbonate and phosphate salts. Solid mineral salts preferentially have a recognized bioactive potential such as the calcium phosphate salts for bones. Both solid and liquid components are admixed to form an injectable liquid slurry or pre-gelled paste that turn in situ into a hybrid uniform gel-like bio-material. | 01-28-2010 |
20100028437 | Hyaluronic Acid-Based Gels Including Lidocaine - Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 02-04-2010 |
20100028438 | Hyaluronic Acid-Based Gels Including Lidocaine - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 02-04-2010 |
20100068281 | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive. | 03-18-2010 |
20100086600 | Flowable Carrier Matrix - A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site. | 04-08-2010 |
20100092562 | SUSTAINED-RELEASE DRUG DELIVERY COMPOSITIONS AND METHODS - The present invention relates to liquid sustained release suspension dosage forms. In particular, the invention encompasses sustained release compositions comprising a dispersed phase, which contains an ion-exchange matrix drug complex, a diffusion controlling membrane coating and a dispersion medium comprising an excipient capable of impeding water activity such that drug dissolution is inhibited prior to administration. Further, the invention provides for compositions wherein several active ingredients associate in a single bead in the dispersed phase, such that the abuse potential of such active ingredients is reduced. The invention also encompasses sustained release formulations of combination drugs comprising an extended release phase and an immediate release phase. The formulations of the invention may be used to treat a variety of conditions and symptoms, including those that require administration of several drugs, such as cold and allergy symptoms. In one of the embodiments, the sustained release composition combines an antihistamine, an antitussive and a decongestant. The invention further provides for methods of making and using such formulations. | 04-15-2010 |
20100098764 | POLYSACCHARIDE GEL FORMULATION HAVING MULTI-STAGE BIOACTIVE AGENT DELIVERY - Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. | 04-22-2010 |
20100104643 | PHARMACEUTICAL COMPOSITIONS - The present invention provides an orally deliverable pharmaceutical composition for the once-daily (OD) administration of trimipramine. The composition comprises a therapeutically effective amount of trimipramine and at least one pharmaceutically acceptable excipient. The compositions of the invention may exhibit one or more of the release profiles defined in this specification. | 04-29-2010 |
20100129451 | Method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery - A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis. The present invention has applications in developing cost effective, controlled drug delivery vehicles from renewable resources, with a potential impact on pharmaceutical research and molecular design and delivery strategies. | 05-27-2010 |
20100129452 | CELLULOSE DERIVATIVE AND METHOD FOR PRODUCTION THEREOF - The invention provides a cellulose derivative having a repeating unit of the formula below, a composition including the cellulose derivative and a phospholipid, a method for production thereof, and an adhesion barrier including the cellulose derivative or the composition. | 05-27-2010 |
20100151029 | Anti-infectious hydrogel compositions - The present invention provides a hydrogel composition capable of preventing the intrusion of micro-organisms into body cavities or body openings of mammals comprising of a poly(N-vinyl lactam), a polysaccharide and water. | 06-17-2010 |
20100159012 | Conjugates of Therapeutically Active Compounds - The present invention discloses modified polymer conjugates of a polymer and a drug having reduced toxicity relative to the unmodified parent compound while retaining substantially the same degree of therapeutic activity as of the unmodified parent compound. | 06-24-2010 |
20100159013 | flavored clay-based therapeutic composition - The subject of the present invention is a flavored therapeutic composition containing a clay as well as active principle, and characterized in that the clay is a dioctahedral smectite and the flavor is encapsulated. | 06-24-2010 |
20100172991 | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation - A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α | 07-08-2010 |
20100178346 | DISC AUGMENTATION WITH HYALURONIC ACID - The present invention relates to materials comprising hyaluronic acid for replacement or augmentation of the nucleus pulposus The materials have a Poisson's ratio of 0.40 to 0.80 based on that of the human nucleus pulposus. | 07-15-2010 |
20100183724 | Hydrogel of Chitosan Carboxyalkylamide, Preparation Thereof and Cosmetic and Dermatological Use Thereof - The present invention relates to a hydrogel of chitosan carboxyalkylamide, characterised in that it has a pH value close to that of the skin, comprised between 6.5 and 7.2, and in that the chitosan carboxy-alkylamide is constituted by 40 to 90 mole % of D-glucosamine N-carboxyalkylamide units of formula (I) | 07-22-2010 |
20100209511 | SUSTAINED RELEASE PHARMACEUTICAL FORMULATION - A sustained release pharmaceutical formulation is disclosed. The formulation comprises a water soluble medicament and a polymer mixture comprising a first component of about 80 weight percent polyvinylacetate combined with about 20 weight percent polyvinyl pyrrolidone; of the total weight of the first component, combined with a second component of a cellulose ether polymer. | 08-19-2010 |
20100226987 | TARGETING CONJUGATES COMPRISING ACTIVE AGENTS ENCAPSULATED IN CYCLODEXTRIN-CONTAINING POLYMERS - A targeting conjugate is provided comprising an active agent, one or more residues of a cyclodextrin (CD)-containing polymer and a biorecognition molecule. The polymer is preferably a peptide or a polypeptide comprising at least one amino acid residue containing a functional side group to which at least one of the CD residues is linked covalently; the biorecognition molecule is covalently bonded directly or via a spacer to the polymer backbone of the CD-containing polymer; and the active agent is noncovalently encapsulated within the cavity of the cyclodextrin residues and/or entrapped within the polymer matrix of the CD-containing polymer. | 09-09-2010 |
20100226988 | CROSS-LINKING OF LOW-MOLECULAR WEIGHT AND HIGH-MOLECULAR WEIGHT POLYSACCHARIDES, PREPARATION OF INJECTABLE MONOPHASE HYDROGELS, POLYSACCHARIDES AND HYDROGELS OBTAINED - A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof. Crosslinked polymers and injectable monophase hydrogels respectively obtainable by each of said processes. | 09-09-2010 |
20100233266 | ARTICLES AND METHODS OF TREATING VASCULAR CONDITIONS - The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site. | 09-16-2010 |
20100233267 | COMPOSITE HYDROGEL - The present invention features a composite hydrogel for use as soft tissue substitutes and transitional three-dimensional support structures. | 09-16-2010 |
20100239673 | Blood compatible nanomaterials and methods of making and using the same - The invention provides blood compatible nanomaterials, biomaterials prepared therewith and blood compatible medical devices fabricated using the biomaterials of the invention. The invention further provides methods of making and using the nanomaterials, biomaterials and medical devices of the invention for the diagnosis, prevention and treatment of medical conditions. The invention further provides methods of using room temperature ionic liquids to make blood compatible nanomaterials. | 09-23-2010 |
20100247652 | Alginate Biomaterials for the Treatment of Hepatic Disorders - The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention. | 09-30-2010 |
20100255100 | STABILIZED PROTEIN CRYSTALS, FORMULATIONS COMPRISING THEM AND METHODS OF MAKING THEM - This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition. The formulations and compositions enhance preservation of the native biologically active tertiary structure of the proteins and create a reservoir which can slowly release active protein where and when it is needed. Methods are provided preparing stabilized formulations using pharmaceutical ingredients or excipients and optionally encapsulating them in a polymeric carrier to produce compositions and using such protein crystal formulations and compositions for biomedical applications, including delivery of therapeutic proteins and vaccines. Additional uses for-the protein crystal formulations and compositions of this invention involve protein delivery in human food, agricultural feeds, veterinary compositions, diagnostics, cosmetics and personal care compositions. | 10-07-2010 |
20100255101 | DEXTRAN-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE - A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum. | 10-07-2010 |
20100266692 | NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN ANIONIC CELLULOSIC POLYMER - A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an anionic cellulosic polymer. | 10-21-2010 |
20100266693 | Controlled release local anesthetic comprising a biologically active non-sulfated glycosaminoglycan matrix - The invention relates to structuring a combination of bioactive materials that are capable of controlled extended release of local anesthesia lasting over 30 hours. | 10-21-2010 |
20100278918 | EXTENDED RELEASE FORMULATION OF NEVIRAPINE - The invention relates to an extended release pharmaceutical composition comprising nevirapine. | 11-04-2010 |
20100285134 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND/OR THE PREVENTION OF OSTEOARTICULAR DISEASES - An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells. | 11-11-2010 |
20100297239 | OSSEOINTEGRATIVE MENISCUS AND CARTILAGE IMPLANTS BASED ON BETA-GLUCAN NANOCOMPOSITES - The present invention provides engineered composite materials for use in medical treatment of injured or degenerated menisci, cartilage, and bone. The composite materials include a cellulosic layer substantially or completely consisting of β-1→4-glucan units, and a hydrogel layer substantially or completely consisting of copolymers of β-1→2-glucan, β-1→3-glucan, and/or β-1→4-glucan, or mixtures of two or all three of these units. Production of the composite materials is achieved in a single culture milieu, using regulation of oxygen availability to control production of the various units and deposition of the layers by | 11-25-2010 |
20100303913 | Method for Nanoencapsulation - Methods of nanoencapsulation are described herein. Embodiments of the method utilize the coacervation of a cationic polyelectrolyte with an anionic polyelectrolyte to form a novel capsular matrix. In particular, the novel methods may be used to encapsulate a suspension of a hydrophobic material such as a carotenoid. The disclosed methods do not require lengthy pH adjustments nor do they require the use of any toxic crosslinking agents. In one embodiment, a method of encapsulation comprises dispersing a hydrophobic compound in an organic solvent to form a solution. The method also comprises admixing an anionic polyelectrolyte and a cationic polyelectrolyte with the suspension to form a mixture. In addition, the method comprises quiescently cooling the mixture so as to cause self-crosslinking of a capsular matrix encapsulating the hydrophobic particles. | 12-02-2010 |
20100303914 | Self-Gelling Alginate Systems and Uses Thereof - Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed. | 12-02-2010 |
20100323016 | MODIFIED RELEASE FORMULATION AND METHODS OF USE - A modified release pharmaceutical formulation includes about 30-70% N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix including hydroxypropylmethylcellulose (HPMC), and an enteric polymer. The pharmaceutical formulation produces a sustained plasma concentration of retigabine following administration to a subject for 4-20 hours longer than the time required for in vitro release of 80% of retigabine. The plasma concentration vs. time profile of this formulation is substantially flat over an extended period lasting for about 4 hours to about 36 hours. A method of treating a disorder characterized by nervous system hyperexcitability includes administering to a subject an effective amount of these pharmaceutical formulations. | 12-23-2010 |
20110002999 | Biopolymer System for Tissue Sealing - A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug. | 01-06-2011 |
20110008443 | PHOTOCROSSLINKED BIODEGRADABLE HYDROGEL - A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation. | 01-13-2011 |
20110008444 | COMPOSITION FOR THE FORMATION OF GELS - A composition, which upon activation, spontaneously forms a cross-linked hydrogel in aqueous liquid, includes:
| 01-13-2011 |
20110014290 | SYSTEM AND METHOD FOR FACILITATING HEMOSTASIS WITH AN ABSORBABLE SPONGE - The present invention provides for a method and apparatus to provide hemostasis at a blood vessel puncture site, having a hemostasis material and a clot formation accelerator, wherein said clot formation accelerator is substantially dispersed throughout said hemostasis material. | 01-20-2011 |
20110020452 | PROGENITOR CELL REPLICATION AND DIFFERENTIATION IN 3D - The present invention is directed to a new approach towards in situ differentiation of tissue progenitor cells, without the coventional requirements of weeks of cellular manipulation and treatment. Such approach circumvents the need for 2D culturing and differentiation of tissue progenitor cells before implanting in a 3D biocompatible matrix, thus providing convenience, cost savings, and time savings. One aspect of the invention provides an engineered tissue composition comprising substantially undifferentiated tissue progenitor cells in a biphasic matrix material, along with growth factors or encapsulated growth factors. Another aspect of the invention includes methods for making the compositions described herein. Another aspect of the invention includes methods of therapeutic treatment using the compositions described herein. | 01-27-2011 |
20110027370 | Sustained Drug Release Composition - The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent. | 02-03-2011 |
20110045077 | ENCAPSULATED PANCREATIC ISLET CELL PRODUCTS AND METHODS OF USE THEREOF - This invention is directed, inter alia, to encapsulated cell products, compositions comprising the same and uses thereof to treat diabetes, and related complications, increase islet cell masses, improve a metabolic profile in a subject, and other related conditions. Processes to produce the encapsulated islet cell product are described. | 02-24-2011 |
20110045078 | PROCESS FOR PRODUCING CELLULOSIC SHAPED ARTICLES, CELLULOSIC SHAPED ARTICLES AND THE USE THEREOF - The invention relates to a process for producing cellulosic shaped articles with stabilized inclusions in a microfine dispersion of nonpolar organic compounds and mixtures by a dry-wet extrusion process. The shaped articles produced in this way exhibit by comparison with unmodified cellulose fibers a substantially increased storage capacity for heat and/or nonpolar active substances. They are suitable in particular for use in textiles for clothing, industrial textiles, leisure, medicine and cosmetics. Potential functional effects imparted include the physical effect of heat storage and/or the uniform and finely meterable storage and release of nonpolar active substances and plant extracts from the interior of the fibers of the shaped articles. It is possible through a suitable choice of the nonpolar portion to produce by this process also fibers capable of absorbing liquid or gaseous nonpolar substances. | 02-24-2011 |
20110070307 | TISSUE REGENERATION - A method including positioning a delivery device at a location in a vessel within a mammalian body, introducing a first treatment agent including a cellular component through the delivery device, and introducing a different second treatment agent disposed in a carrier through the delivery device. A method including identifying an infarct region within myocardial tissue and a border region of perfused tissue adjacent the infarct region, introducing a treatment agent including a cellular component to the border region, and introducing a plurality of microparticles to the infarct region. A kit including a treatment agent including a cellular component in a form suitable for percutaneous delivery, and a separate amount of a plurality of microparticles in a form suitable for percutaneous delivery. | 03-24-2011 |
20110076332 | Dextran-chitosan based in-situ gelling hydrogels for biomedical applications - A biodegradable hydrogel comprises a water-soluble dextran having aldehyde groups cross-linked with a water-soluble chitosan. Various chemical agents may be encapsulated in the hydrogel or bonded thereto for controlled release. The hydrogel may be applied as a coating to reduce the likelihood of bacterial attachment and biofilm growth; used in tissue engineering applications to prevent tissue ingrowth; or used as a matrix in which cells may proliferate. The components of the hydrogel can be applied sequentially as a spray or by immersion and will gel spontaneously at environmental or physiological temperatures. | 03-31-2011 |
20110081417 | SURGICAL COMPOSITIONS - The present disclosure relates to multi-component hydrogels. The hydrogels may include a natural component having nucleophilic functional groups as well as an electrophilic component. In embodiments, at least one of the components may be branched, having drugs, antibodies, enzymes, and the like incorporated therein, which may react with at least one of the other components of the hydrogel. | 04-07-2011 |
20110097408 | CHITOSAN-BASED MATRICES AND USES THEREOF - This invention relates a controlled release delivery composition for an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination, using a chitosan-glycerophosphate (CGP) hydrogel and an agent or a bio-materials. Additionally, provided methods of treating an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination. | 04-28-2011 |
20110104284 | HYALURONIC ACID DERIVATIVE BASED THREE-DIMENSIONAL MATRIX - Use of a biological material containing: e) a three-dimensional matrix based on a hyaluronic acid derivative and optionally f) chondrocytes and/or mesenchymal cells partially or completely differentiated towards chondrocytes for the preparation of a graft to be surgically implanted into a joint cartilage damaged by or to be protected against a degenerative and/or inflammatory pathology. | 05-05-2011 |
20110111035 | INFLAMMATION-REGULATING COMPOSITIONS AND METHODS - The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1β, an anti-IL-6, an anti-TNF-α, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration. The RGD peptide functions to promote cellular proliferation, migration and attachment to the polymer. The monoclonal antibody functions to inhibit the inflammatory response. | 05-12-2011 |
20110117198 | COMPOSITIONS OF SEMI-INTERPENETRATING POLYMER NETWORK - Novel compositions consisting of semi-interpenetrating network of cross-linked water soluble derivatives of basic polysaccharides and a non-cross-linked component, which is an anionic polysaccharide are provided. Methods for the production of such compositions are also disclosed. Preferably the basic polysaccharide is chitosan or a derivative thereof and the anionic polysaccharide is hyaluronic acid. The compositions can be formed into gels or films, for example, and thus find use in a wide range of medical applications in the fields of dermatology, plastic surgery, urology and orthopaedics. | 05-19-2011 |
20110129536 | NANOCOMPOSITE MATERIALS BASED ON METALLIC NANOPARTICLES STABILIZED WITH BRANCHED POLYSACCHARIDES - The present invention provides nanocomposite systems made of metallic nanoparticles stabilized with branched cationic polysaccharides, in particular alditolic or aldonic mono- and oligo-saccharidic derivatives of chitosan, and their preparation obtainable with aqueous solutions of these polysaccharides in the presence or absence of reducing agents. The peculiar chemical and physical-chemical features of these polysaccharides allow to form metallic nanoparticles homogeneously dispersed in the polysaccharidic matrix and an effective stabilization thereof. The properties associated with the nanometric dimensions and the presence of biological signals on polymeric chains may be exploited in applications with antimicrobial activities and of molecular biosensors. | 06-02-2011 |
20110135733 | ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS - There is provided a method of conjugating a polymer containing a free aldehyde group with a flavonoid in the presence of an acid catalyst, such that the polymer is conjugated to the C6 or C8 position of the flavonoid A ring. The resulting conjugates may be used to form delivery vehicles to deliver high doses of flavonoids, and may also be used as delivery vehicles to deliver an additional bioactive agent. | 06-09-2011 |
20110165249 | PHARMACEUTICAL SOLID PREPARATION - An object of the present invention is to provide a gradual disintegration-type, sustained-release pharmaceutical solid preparation whose pharmacologically active substance release behavior is controlled. The solid pharmaceutical preparation of the present invention is a matrix-type preparation containing: (a) a pharmacologically active substance; (b) calcium polycarbophil; and (c) a specific sugar and/or sugar alcohol. | 07-07-2011 |
20110171310 | HYDROGEL COMPOSITIONS COMPRISING VASOCONSTRICTING AND ANTI-HEMORRHAGIC AGENTS FOR DERMATOLOGICAL USE - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 07-14-2011 |
20110171311 | STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 07-14-2011 |
20110189292 | DERMAL FILLERS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF - The present specification provides compositions useful as dermal fillers and methods using such compositions to treat a condition of skin. | 08-04-2011 |
20110200676 | CROSS-LINKED OXIDATED HYALURONIC ACID FOR USE AS A VITREOUS SUBSTITUTE - A composition comprising a polymer that comprises oxidated hyaluronic acid cross-linked by a dihydrazide is disclosed. The polymer is a hydrogel exhibiting the following properties: a) transparent and colorless; and b) transforming from a liquid state into a gel-matrix at 37° C. These characteristics make it useful as a vitreous humor substitute. | 08-18-2011 |
20110229573 | PROCESS OF MANUFACTURING A LYOPHILIZED FAST DISSOLVING, MULTI-PHASIC DOSAGE FORM - A multi-phasic, lyophilized, fast-dissolving dosage form (FDDF) for the delivery of a pharmaceutically active ingredient is prepared by sequential dosing of a formulation containing a non-gelling matrix forming agent and a formulation containing a gelling gelatin. | 09-22-2011 |
20110229574 | POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATION - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 09-22-2011 |
20110236486 | METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS THEREOF - A system and method are provided for controlling an internal combustion engine driving a generator/welder or a stand-alone generator. Controlling the engine may include altering the engine speed based upon a detected demand on the generator and/or operating parameters of a welder. For example, the engine speed may be increased based on a detected draw on the generator and/or the operating parameters of the welder. In addition, the engine speed may be automatically decreased to a non-standard idle speed or the engine may be automatically turned off if no demand is detected for a period of time. Additionally, the engine speed may be increased if only frequency-insensitive demands are detected on the generator. Combinations of these and further methods may be executed. Various devices are provided for implementing the above methods. | 09-29-2011 |
20110274756 | METHOD AND MEMBRANE FOR TISSUE REGENERATION - Tissue regeneration or grafting is promoted utilizing a structure including a multi-layer sheet of collagen membrane material which includes a purified collagen barrier sheet material derived from natural collagen-containing tissue, the barrier sheet material including a barrier layer with an outer smooth barrier face and a fibrous face opposite the smooth barrier face. The structure further includes a matrix layer of collagen sponge material adjacent to the fibrous face. The matrix layer of collagen sponge material is resorbed by a body of a subject at a substantially faster rate than the barrier sheet material. | 11-10-2011 |
20110293722 | HYDROGEL SPONGES, METHODS OF PRODUCING THEM AND USES THEREOF - A macroporous hydrogel sponge is provided selected from: (i) a synthetic polymer hydrogel sponge, and (ii) a synthetic polymer-polypeptide conjugate hydrogel sponge, the macroporous hydrogel sponge being at least 20% porous and having a pore diameter of 50-1000 μm, wherein said synthetic polymer is crosslinked to an extent determined by effecting the crosslinkig of the synthetic polymer or synthetic polymer-polypeptide conjugate in the presence of at least about 30% by weight crosslinking agent. | 12-01-2011 |
20110311632 | STABLE CHITOSAN HEMOSTATIC EXTERNAL PATCH AND METHODS OF MANUFACTURE - Hemostatic products with improved stability are prepared from crosslinked chitosan hemostatic compositions. The crosslinked chitosan hemostatic compositions have improved stability and can be prepared into a variety of medical devices in various shapes and sizes so as to be usable for inhibiting blood flow and ooze from substantially any type of bleeding site. For example, the chitosan compositions can be prepared into hemostatic gauze pads, bandages, wrappings, wound dressings, wound coverings, wound dressings, incision dressings, sealers, sheets, rolls, combinations thereof, and the like. | 12-22-2011 |
20110318416 | BIORESORBABLE POLYMER MATRICES AND METHODS OF MAKING AND USING THE SAME - A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the reaction mixture of 6 or less. The composition may include a release agent for the controlled release of the bioactive agent from the composition. A bioactive agent may therefore be administered to a body site in need of the same by providing a first aliquot portion of a reaction mixture comprising an oxidized dextran solution, and a second aliquot portion of a reaction mixture comprising a mixture of solids comprised of a dihydrazide, a bioactive agent, and a solid acid which is present in an amount sufficient to achieve a pH of the reaction mixture of 6 or less, mixing the first and second aliquot portions to form the reaction mixture thereof, and thereafter installing the reaction mixture at the body site and allowing a solidified bioerodible drug delivery composition to be formed thereby in situ. The present invention may be provided in the form of a kit comprised of a double syringe which respectively contains the first and second aliquot portions of the reaction mixture so that the same may be mixed just prior to use. | 12-29-2011 |
20120009263 | GRANULAR DELIVERY SYSTEM - A granular delivery system and a method of preparing the same by creating a melt emulsion having a continuous phase and a dispersed active, wherein the continuous phase includes trehalose and a hydrogenated starch hydrolysate having number average degree of polymerization, DPn, of between 5 and 100, or a number average molecular weight, Mn of between 800 and 16000 Da, forcing the melt emulsion through an die or orifice to form an extrudate, cooling and granulating the extrudate to form granules of the delivery system and optionally drying the granules. | 01-12-2012 |
20120034307 | Aqueous gel formulation and method for inducing topical anesthesia - Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal. | 02-09-2012 |
20120189699 | POLYSACCHARIDE GEL FORMULATION HAVING MULTI-STAGE BIOACTIVE AGENT DELIVERY - Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. | 07-26-2012 |
20120328699 | METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS - The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP). | 12-27-2012 |
20120328700 | METHODS AND COMPOSITIONS FOR REGENERATING CONNECTIVE TISSUE - Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament. | 12-27-2012 |
20130017264 | ALGINATE TUBE DRUG DELIVERY SYSTEM AND METHOD THEREFORAANM KHANDARE; Jayant J.AACI MumbaiAACO INAAGP KHANDARE; Jayant J. Mumbai INAANM Boldhane; Sanjay P.AACI MumbaiAACO INAAGP Boldhane; Sanjay P. Mumbai IN - A drug delivery system which comprises alginate tube that is prepared by coating a substrate with alginate gel. One or more therapeutic drugs may also be present in the alginate gel or in the cavity of the tube. The activity of the alginate drug delivery system is highly adjustable so that the release may be controlled as required. The rate at which the system releases the drug and the concentration of the drug released can be adjusted by varying; the number of layers of the alginate tubes, the number of open or closed ends of the tubes, or the number of tube layers containing the drug. | 01-17-2013 |
20130108700 | METHODS AND COMPOSITIONS FOR WOUND TREATMENT | 05-02-2013 |
20130202705 | ALCOHOL-RESISTANT FORMULATIONS - This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance. | 08-08-2013 |
20130302420 | OCULAR BIODEGRADABLE DRUG IMPLANT AND METHOD OF ITS USE - A biodegradable drug implant includes a PLG matrix and a non-steroid anti inflammation drug, for example diclofenac sodium. The implant is inserted into the eye in the anterior chamber, for example in the ciliary sulcus, following eye surgery. A method for treating and or preventing inflammation of the eye following eye surgery includes placing the implant in the anterior portion of the eye. | 11-14-2013 |
20140037731 | Method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery - A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis. The present invention has applications in developing cost effective, controlled drug delivery vehicles from renewable resources, with a potential impact on pharmaceutical research and molecular design and delivery strategies. | 02-06-2014 |
20140134250 | OXYMORPHONE CONTROLLED RELEASE FORMULATIONS - The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. | 05-15-2014 |
20140170219 | COMPOSITION AND METHOD FOR TREATING HPV - Described are lyophilized compositions comprising cidofovir, hydroxypropyl methylcellulose (HPMC) or hydroxyethylcellulose (HEC) and, optionally, a plasticizer. In particular, described are such compositions that form a sheet-shaped porous solid matrix. Also described are methods for producing such compositions and their use in treating human papillomavirus (HPV) infections and HPV-associated malignancies, in particular, HPV lesions and cervical cancer. | 06-19-2014 |
20140199394 | CONTROLLED RELEASE HYDROCODONE - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 07-17-2014 |
20140271867 | FILM DELIVERY SYSTEM FOR ACTIVE INGREDIENTS - The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including testosterone esters, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided. | 09-18-2014 |
20140271868 | TREATMENT OF ACHONDROPLASIA WITH ENCAPSULATED CNP-SECRETING CELLS - The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP). | 09-18-2014 |
20140322327 | DRUG DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF BIOACTIVE AGENTS - A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it. | 10-30-2014 |
20140377354 | FLAVOURED CLAY-BASED THERAPEUTIC COMPOSITION - The subject of the present invention is a flavoured therapeutic composition containing a clay as the active principle, and characterized in that the clay is a dioctahedral smectite and the flavour is encapsulated. | 12-25-2014 |
20150110874 | SUSTAINED RELEASE FORMULATIONS OF LORAZEPAM - A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions. | 04-23-2015 |
20150290360 | METHOD OF PREPARING AN IMPLANTABLE NEUROENDOPROSTHETIC SYSTEM - A method of making an implantable neuroendoprosthetic system for transubstantiation of defects of brain, spinal cord and vegetative nervous system in a mammal in reconstructive neurosurgical operations provides a heterogeneous collagen-containing matrix for implantation, a cell preparation of autologous cells of a patient, and the cell preparation is perfused into said matrix to make an elastic cell-biopolymer biologically active mass. The cell preparation comprises placed in a NaCl solution at least one type of cells from a group comprising neural stem cells (NSC), neuroglial ensheathing cells (NGEC), endothelial cells with CD34+ marker (EC), and purified mononuclears (MN). The mass can be additionally subjected to electromagnetic radiation at 1-10 GHz before implanting. | 10-15-2015 |
20150313912 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF MAKING THE SAME - The present disclosure comprises antimicrobial compositions and devices comprising silver compounds that resist heat and light discoloration. In one aspect, the said compounds comprise silver and at least one s-triazine ring or moiety. In another aspect, the antimicrobial compositions are hydrogels that are effective against broad spectrum of common pathogens including MRSA and VRE and are suitable for treating human or animal wounds and burns. The methods of the present disclosure comprise treating medical and non-medical devices and articles with compositions comprising the silver compounds to impart antimicrobial property. | 11-05-2015 |
20150352156 | GROWTH FACTOR SEQUESTERING AND PRESENTING HYDROGELS - Provided herein are hydrogel cell matrices, hydrogel cell matrix systems for the support, growth, and differentiation of a stem cell or progenitor cell and methods for making such hydrogel cell matrices. | 12-10-2015 |
20160101044 | LONG-LASTING INJECTABLE DRUG RELEASING GEL COMPOSITION AND METHOD OF MANUFACTURING THE SAME - A gel composition and method of manufacturing the same is discussed. The gel composition includes a plurality of chitosan spheres, an alkaline chitosan stabilizing agent, a chitosan decomposition enzyme and a drug. The chitosan spheres are formed by chitosan self-assembly. The alkaline chitosan stabilizing agent connects the chitosan spheres to form a gel body. The chitosan decomposition enzyme scatters in the gel body and decomposes the gel composition at a temperature of 20 to 40 degree Celsius. The drug scatters in the gel body. | 04-14-2016 |
20160114048 | THERMOLABILE DRUG RELEASE FORMULATION - The present invention relates to a drug release formulation, in particular a sustained release formulation for ophthalmic applications and a method of preparing same. The method is based on the hydration of a given solid polymeric matrix material under mild conditions, allowing versatility with respect to the drug to be formulated. Both said solid polymeric matrix material as well the API hydrated formulation is an object of the present invention. The thus obtained material is particularly suitable for prolonged and sustained delivery of medication to the eye. Thus in a further aspect, the present invention provides the use of said solid polymeric matrix material as well the API hydrated formulation, in ophthalmic applications. | 04-28-2016 |
20160175478 | Use of a Haemoglobin for the Preparation of Dressings and Resulting Dressings | 06-23-2016 |
20160250154 | FILM DELIVERY SYSTEM FOR ACTIVE INGREDIENTS | 09-01-2016 |
20170232134 | CHITOSAN SUPERFINE FIBER SYSTEMS | 08-17-2017 |
20190142760 | Particle-Based Multi-Layer Therapeutic Delivery Device and Method | 05-16-2019 |
20190142959 | HYALURONIC ACID DERIVATIVES INTO WHICH CATIONIC AND HYDROPHOBIC GROUPS ARE INTRODUCED | 05-16-2019 |